RxDoctor Payments Data

George Bousamra, MD

Interventional Cardiology · Somerset, PANPI 1447369020

Payments from drug & device makers

$6,469in general payments, 2019–2025

Across 350 payments — averaging $18.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Amgen$641
  • Amarin Pharma, Inc.$444
  • Merck$432
  • Boehringer Ingelheim$419
  • E.r. Squibb & Sons, L.L.C.$406
  • plus $3K from 19 others

What the payments were for

  • Food & beverage$6,41599%
  • Education$541%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,469 in reported general payments places this provider in the 40th percentile of 281 interventional cardiology providers in Pennsylvania.

See all interventional cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$64,408
Medicare patients
300
Services billed
695

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban236$273,078
EntrestoSacubitril/Valsartan147$147,903
XareltoRivaroxaban141$133,861
Repatha SureclickEvolocumab133$104,685
FerriproxDeferiprone12$84,515
JardianceEmpagliflozin62$67,993
FarxigaDapagliflozin Propanediol24$25,233
BrilintaTicagrelor20$18,606
VascepaIcosapent Ethyl26$18,052
VerquvoVericiguat11$13,008
Praluent PenAlirocumab17$10,579
Pitavastatin Calcium37$7,143
Icosapent Ethyl44$6,987
Nebivolol Hcl144$6,828
Repatha SyringeEvolocumab12$6,627

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$323$273,078236 claims
NovartisEntresto$375$147,903147 claims
Johnson & JohnsonXarelto$1,308$133,861141 claims
Boehringer IngelheimJardiance$419$67,99362 claims
AstraZenecaFarxiga, Brilinta$283$43,83944 claims
MerckVerquvo$432$13,00811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 281 interventional cardiology providers in Pennsylvania.

Other interventional cardiology in Somerset

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →